The Natural Solutions Foundation keeps an eye on the news for you. And when we see relationships, we point them out. So we wonder:
1. Could the fact that Warren Buffet turned over a vast amount of money to the Bill and Melinda Gates Foundation (BMGF) be related to the fact that BMGF is in the process of making a great deal of that money back for him through its huge subsidies of vaccine manufacturers?
2. Could it be that the report that we have received that vaccines delivered by BMGF to third world countries have twice the mercury (thimerisol) present in American vaccines are true?
3. Could it be that the fact that the Rotavirus vaccine which causes and increased risk of pneumonia-related deaths and convulsions is slated for FDA approval anyway is not an accident or an oversight, but part of a program to extract every possible bit of profit from vulnerable populations regardless of the consequences to members of those populations (babies, for example)?
4. Could it be that the approval process by which FDA makes its decisions is so corrupted that no product or food approved by that organization can be assumed to be safe?
5. Could it be that the deaths of babies or their neurological damage is of little or no consequence to the decision-makers at the FDA and the corporate chiefs at the helms of the drug companies?
Read the two articles below and answer those questions for yourself. If your answer is “Yes” to those questions, you need the Natural Solutions Foundation on your side. Share this information widely. Sign up for the free and secure Natural Solutions Foundation Health Freedom eAlerts (http://drrimatruthreports.com/index.php?page_id=187) and make a generous recurring donation (http://drrimatruthreports.com/index.php?page_id=189) for a tax deductible way to safeguard your health and your health freedom.
Want more information on vaccinations and vaccine hazards? Join the No-Forced-Vaccination Forum today. Click here (http://groups.yahoo.com/group/no-forced-vaccination/join)
to become a member of this vital community of dedicated health freedom advocates focused on maintaining vaccination choice.
Yours in health and freedom,
Dr. Rima
Rima E. Laibow, MD
Medical Director
Natural Solutions Foundation
www.HealthFreedomUSA.org
www.GlobalHealthFreedom.org
FDA ties pneumonia deaths to infant vaccine
Agency panel considering approval of oral medicine for diarrhea virus
updated 11:20 a.m. ET Feb. 15, 2008
WASHINGTON – GlaxoSmithKline Plc’s rotavirus vaccine is associated with increased pneumonia-related deaths and other adverse reactions, U.S. regulatory staff said in documents posted on Friday.
The review comes ahead of a Food and Drug Administration advisory meeting next Wednesday to consider approval of the oral vaccine to prevent the most common cause of severe diarrhea and dehydration among infants and young children in the world.
FDA staff said its analysis of 11 studies revealed that in the largest trial, there was a statistically significant increase in deaths related to pneumonia compared with placebo, documents posted on the FDA’s Web site said.
That study, which enrolled about 63,000 children, also found an increase in convulsions in children given the drug, named Rotarix. Another study found an increased rate of bronchitis, compared with placebo.
In a conclusion section, the FDA documents noted the pneumonia-related deaths and convulsions, but did not appear to make a recommendation to the advisory panel.
That expert panel will weigh the staff review, but makes its own recommendation, which is typically followed by the FDA.
Triangle Business Journal
Friday, February 15, 2008 – 10:59 AM EST
GlaxoSmithKline’s [GSK] rotavirus vaccine, called Rotarix, is associated with an increased risk of convulsions and pneumonia-related deaths in children taking it, according to a review by the U.S. Food and Drug Administration.
Rotovirus is the most common cause of severe diarrhea and dehydration among infants and young children.
The study, which enrolled about 63,000 children, found a statistically significant increase in convulsions and deaths related to pneumonia compared with a placebo, the review says.
The staff review is one consideration among many that an expert panel at the FDA will weigh when deciding whether to approve the drug.
The news comes shortly after Berkshire Hathaway, the company run by billionaire investor Warren Buffett, revealed in filings late Thursday that it has made a significant investment in GSK.
Buffett’s investment in GSK is valued at about $65.4 million and follows a series of Berkshire stock purchases in health-care companies, including UnitedHealth Group, WellPoint, Johnson & Johnson and Sanofi-Aventis SA.
GSK employs about 6,000 people in the Triangle, although the company recently announced a worldwide, three-year restructuring plan that will include significant job cuts.
GSK’s stock opened at $44 on Friday from a previous closing price of $43.32.
